The Pathogenesis, Treatment, and Possible Prevention of Uremic Bone Disease

  • Joseph M. Letteri


Uremic bone disease can be classified into three major types based on histomorphometric analysis of double tetracycline labeling of iliac crest bone obtained by trephine (Table I). Type I consists of patients with high-turnover bone disease. Type II consists of patients with high-turnover bone disease in which the major manifestation of the abnormal mineral metabolism associated with uremia is metastatic calcification. Type III consists of patients with low turnover bone disease.


Parathyroid Hormone Bone Disease Skeletal Defect Marrow Fibrosis Metastatic Calcification 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coburn JW, Massry SG (eds): Uses and actions of 1,25(OH)2D3 in uremia. Contrib Nephrol 18:1–217, 1980.Google Scholar
  2. 2.
    Healy MD et al: Effects of long-term therapy with 1,25(OH)2D3 in patients with moderate renal failure. Arch Intern Med 140: 1030, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Massry SG, Coburn JW: Divalent ion metabolism and renal osteodystrophy, in Massry SG, Sellers AL (eds): Clinical Aspects of Uremia and Dialysis. Springfield, Ill, Charles C Thomas, 1976, pp 304–399.Google Scholar
  4. 4.
    Massry SG, Goldstein DA: Is calcitriol (1,25(OH)2D3) harmful to renal function? JAMA 242: 1875, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Massry SG, Goldstein DA, Malluche HH: Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Kidney Int 18: 409, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • Joseph M. Letteri
    • 1
    • 2
  1. 1.Division of Renal Diseases, Department of MedicineNassau County Medical CenterStony BrookUSA
  2. 2.Department of MedicineState University of New York at Stony BrookStony BrookUSA

Personalised recommendations